Formulation Development
ImmuneSensor Therapeutics Initiates Dosing in Phase 1 Trial of Lead cGAS Inhibitor Drug Candidate
ImmuneSensor Therapeutics recently announced the first dose level cohort of healthy volunteers has been dosed in a Phase 1 randomized, double-blinded, placebo-controlled clinical trial of…
GRIN Therapeutics Announces Initiation of Astroscape Clinical Trial of Radiprodil for Treatment of Tuberous Sclerosis Complex & Focal Cortical Dysplasia Type II
GRIN Therapeutics Inc. recently announced initiation of the Astroscape study, its global open-label clinical trial of radiprodil, an investigational, selective and potent negative allosteric modulator…
Veranova Expands Advisory Board With Distinguished Industry Leaders
Veranova recently announced the appointment of two distinguished industry leaders, Dr. Rajni Aneja and Dr. Bradley L. Pentelute, to its Advisory Board…..
NeOnc Technologies Receives Pharma Tech Outlook’s Top Drug Delivery Platform Award for 2024
NeOnc Technologies Holdings, Inc. has been recognized by Pharma Tech Outlook as the Top Drug Delivery Platform of 2024. According to the publisher of the…
Avillion Announces Positive High-Level Results From Phase 3 BATURA Trial With AstraZeneca’s Inhaled Anti-Inflammatory Medication Airsupra in Asthma Patients
Avillion Life Sciences Ltd recently announced the ongoing BATURA Phase 3b trial evaluating AstraZeneca’s Airsupra (albuterol/budesonide) in patients with intermittent or mild persistent asthma has…
Actylis Acquires Pharm-Rx, a Leading Value-Added Supplier of Specialty Ingredients for the Vitamin, Mineral, Supplement & Pharmaceutical Industries
Actylis recently announced the strategic acquisition of Pharm-Rx, a leading value-added supplier of specialty ingredients for the vitamin, mineral, and supplement (VMS) and pharmaceutical industries.…
Microbiotica Announces First Patient Dosed in its International Phase 1b Trial, MELODY-1 of MB097 Precision Microbiome Co-Therapy in Advanced Melanoma
Microbiotica recently announced the first patient has been dosed in its advanced melanoma (MELODY-1) trial. This international trial is due to recruit up to 40…
SGS Announces Expansion of Biopharmaceutical Testing Capabilities
SGS recently announced it has added new capacity and capabilities at its center of excellence in Lincolnshire, IL. This expansion adds new instrumentation and expertise…
Cybrexa Therapeutics Announces First Patient Dosed With First-in-Class Peptide-Drug Conjugate in Phase 2 Trial in Ovarian Cancer
Cybrexa Therapeutics recently announced the first patient has been dosed in a Phase 2 clinical trial evaluating CBX-12 in patients with platinum-resistant or refractory ovarian…
Akoya’s Leading Spatial Proteomics Platforms Selected for Use by Ground-Breaking UK-Based MANIFEST Consortium to Revolutionize Cancer Immunotherapy
Akoya Biosciences, Inc. recently announced the its PhenoCycler Fusion and PhenoImager HT spatial proteomics platforms will be used to analyze tissue samples as part of…
Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers
Monopar Therapeutics Inc. recently announced the Phase 1a clinical trial for its novel therapeutic radiopharmaceutical MNPR-101-Lu (MNPR-101 conjugated to lutetium-177) is now active and recruiting…
Abivax Announces First Patient Enrolled in Phase 2b Trial of Obefazimod in Crohn’s Disease
Abivax SA recently announced the first patient was enrolled in its Phase 2b ENHANCE-CD (NCT06456593) trial evaluating obefazimod in patients with Crohn’s disease (CD). The…
Biodexa Provides Update on Progression Free & Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma
Biodexa Pharmaceuticals PLC recently announced an update in respect of its open label Phase 1 study of MTX110 in recurrent glioblastoma. In October 2023, the…
Recipharm Strengthens Pharmaceutical Development Capabilities With Strategic Investments
Recipharm is expanding its pharmaceutical development capabilities, through targeted investments and the integration of cutting-edge technologies. This investment bolsters its services for early- and late-…
BioDuro-Sundia Launches New Compound Management Center, Strengthening Drug Discovery Services
BioDuro-Sundia recently announced the launch of a new Compound Management Center at its Waigaoqiao site in the Shanghai Free-Trade Zone, China. This new center enables…
Legend Biotech to Establish New, State-of-the-Art Cell Therapy R&D Facility in Philadelphia
Legend Biotech Corporation recently announced it is establishing a new, state-of-the-art research and development (R&D) facility in Philadelphia, PA, to advance its portfolio of next-generation…
Hovione & Zerion Pharma Create Joint Venture to Further Expand Use of Dispersome Technology
Hovione Farmaciência, S.A. and Zerion Pharma A/S recently announced they have expanded their partnership to accelerate the development of the Dispersome technology platform and further…
First Patient Dosed in Phase 2 Trial of TLX250-CDx for Detection of Recurrent Kidney Cancer After Surgery
Telix Pharmaceuticals Limited recently announced the first patient has been dosed in a Phase 2 trial exploring the clinical utility of Telix’s first-in-class investigational PET1…
Bora Appoints First Division President of its CDMO Business
Bora Pharmaceuticals Co., Ltd. recently announced the appointment of J.D. Mowery to the newly created position of Division President of Bora’s CDMO business. “Through our…
DRUG DELIVERY - Advancements in Transdermal Delivery Systems: A Focus on Invisicare® Technology for Obesity Treatment
James A. Roszell, PhD, and Doreen McMorran demonstrate how this technology has demonstrated potential in the transdermal administration of glucagon-like peptide-1 (GLP-1) agonists and cannabinoid receptor type 1 (CB-1) antagonists, primarily targeting obesity management and other conditions requiring glucose regulation.
